Several GPRC5D-targeted agents are currently being evaluated in clinical trials for the treatment of MM (Table 3), and these agents can be developed as both single-targeted therapies focusing solely on GPRC5D or as dual-targeted therapeutics in combination with BCMA-directed therapies [214, 262]. The gene discussed is GPRC5D; the disease is Miyoshi myopathy.